Kyle Gano, CEO of Neurocrine Biosciences NBIX, has filed 0 purchases and 21 sales on the open market. Over the past 12 months that comes to a net sale of $4.9M. The latest trade was on 02/13.

KG

KG

Kyle Gano

CEO

Company

Neurocrine Biosciences NBIX

First filing

23/02/02

Trades

67 trades

Buys / sales

0 / 21

12-month net buying

−$4.9M

Last trade

02/13

FollowShare

Trading activity

6 months1 year2 years5 yearsAll

Transactions

Company	Trade type	Traded	Filed	Shares	Price	Value	Holding change
Neurocrine BiosciencesNBIX	Open-market sale10b5-1 plan	01/16	01/20	36,400 sh2 trades	$132.70avg.	$4,830,298.12	−20.6%
Neurocrine BiosciencesNBIX	Open-market sale	25/11/04	25/11/04	300 sh	$141.97	$42,591	−0.2%
Neurocrine BiosciencesNBIX	Open-market sale10b5-1 plan	25/02/13	25/02/14	2,558 sh2 trades	$116.85avg.	$298,900.84	−1.8%
Neurocrine BiosciencesNBIX	Open-market sale10b5-1 plan	25/02/10	25/02/12	980 sh	$118.39	$116,022.2	−0.7%
Neurocrine BiosciencesNBIX	Open-market sale10b5-1 plan	25/01/31	25/02/04	1,541 sh	$152.87	$235,572.67	−1.1%
Neurocrine BiosciencesNBIX	Open-market sale10b5-1 plan	25/01/15	25/01/17	65,000 sh2 trades	$141.50avg.	$9,197,500	−32.4%
Neurocrine BiosciencesNBIX	Open-market sale10b5-1 plan	24/02/13	24/02/15	1,352 sh	$132.89	$179,667.28	−1.0%
Neurocrine BiosciencesNBIX	Open-market sale10b5-1 plan	24/02/06–24/02/08	24/02/08	2,580 sh2 trades	$139.16avg.	$359,036	−1.9%
Neurocrine BiosciencesNBIX	Open-market sale10b5-1 plan	24/01/31	24/02/02	1,541 sh	$140.70	$216,818.7	−1.2%
Neurocrine BiosciencesNBIX	Open-market sale10b5-1 plan	24/01/02	24/01/04	75,000 sh2 trades	$131.47avg.	$9,860,066.52	−36.5%
Neurocrine BiosciencesNBIX	Open-market sale10b5-1 plan	23/08/21	23/08/23	2,132 sh	$107.41	$228,998.12	−1.6%
Neurocrine BiosciencesNBIX	Open-market sale	23/02/06–23/02/08	23/02/08	17,004 sh4 trades	$102.79avg.	$1,747,901.28	−11.7%
Neurocrine BiosciencesNBIX	Open-market sale	23/01/31	23/02/02	1,541 sh	$109.98	$169,479.18	−1.3%